{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:43:50Z","timestamp":1794098630626,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2021R1A2C1010900"],"award-info":[{"award-number":["NRF-2021R1A2C1010900"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2023-0070"],"award-info":[{"award-number":["6-2023-0070"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jhep.2024.03.003","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T04:24:36Z","timestamp":1710131076000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-6414","authenticated-orcid":false,"given":"Seo Hee","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7173-0324","authenticated-orcid":false,"given":"Jina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1794-5951","authenticated-orcid":false,"given":"Jinsil","family":"Seong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.03.003_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.03.003_bib2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.03.003_bib3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.03.003_bib4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.03.003_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0022-5347(17)71516-9","article-title":"Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy","volume":"42","author":"Dellinger Barney","year":"1939","journal-title":"J Urol"},{"key":"10.1016\/j.jhep.2024.03.003_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00000658-199312000-00002","article-title":"Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma","volume":"218","author":"Gadd","year":"1993","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2024.03.003_bib8","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.1994.12.7.1491","article-title":"Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie","volume":"12","author":"Nordlinger","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.5183","article-title":"Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach","volume":"247","author":"Lorber","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jhep.2024.03.003_bib12","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2024.03.003_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib16","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib17","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.03.003_bib18","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jhep.2024.03.003_bib20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.jhep.2024.03.003_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2024.03.003_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2024.03.003_bib25","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00432-021-03553-2","article-title":"Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma","volume":"147","author":"Kim","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/JHC.S290197","article-title":"Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis","volume":"8","author":"Kim","year":"2021","journal-title":"J\u00a0Hepatocell Carcinoma"},{"key":"10.1016\/j.jhep.2024.03.003_bib27","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/01621459.1937.10503522","article-title":"The use of ranks to avoid the assumption of normality implicit in the analysis of variance","volume":"32","author":"Friedman","year":"1937","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.jhep.2024.03.003_bib29","article-title":"Local treatment of hepatocellular carcinoma with oligometastases: a systematic Review and meta-analysis","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2024.03.003_bib30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/jrr\/rraa067","article-title":"Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: a single-institutional study","volume":"61","author":"Matoba","year":"2020","journal-title":"J\u00a0Radiat Res"},{"key":"10.1016\/j.jhep.2024.03.003_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jjco\/hyac028","article-title":"Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08)","volume":"52","author":"Jo","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235848","article-title":"Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04)","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2024.03.003_bib33","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3748\/wjg.v29.i24.3871","article-title":"Stereotactic body radiotherapy combined\u00a0with\u00a0sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: a phase II clinical trial","volume":"29","author":"Chen","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.03.003_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic Review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.03.003_bib36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?","volume":"13","author":"Bernstein","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3748\/wjg.v27.i10.919","article-title":"Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma","volume":"27","author":"Lee","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.03.003_bib38","doi-asserted-by":"crossref","first-page":"41242","DOI":"10.18632\/oncotarget.17168","article-title":"Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2024.03.003_bib39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.radonc.2017.11.027","article-title":"Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy","volume":"129","author":"Kim","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12885-016-2379-x","article-title":"Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer","volume":"16","author":"Fleckenstein","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2024.03.003_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.radonc.2019.10.004","article-title":"Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy","volume":"144","author":"Sharma","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdt537","article-title":"Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival","volume":"25","author":"de Vin","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jhep.2024.03.003_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2014.12.003","article-title":"Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases","volume":"114","author":"Fode","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib45","first-page":"58","article-title":"Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up","volume":"16","author":"Agolli","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jhep.2024.03.003_bib46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/A:1008264412398","article-title":"Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients","volume":"9","author":"Apolone","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2024.03.003_bib47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement","author":"Groenvold Mck","year":"1997","journal-title":"J\u00a0Clin Epidemiol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824001545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824001545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:41:03Z","timestamp":1783960863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824001545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0168827824001545"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.03.003","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}